Evidence map›Paper›PMID 39527397›Full record

ArticleJournal of epidemiology and global health2024

Assessing COVID-19 Vaccine Effectiveness and Risk Factors for Severe Outcomes through Machine Learning Techniques: A Real-World Data Study in Andalusia, Spain.

Álvaro Serrano-Ortiz, Juan Luis Romero-Cabrera, Jaime Monserrat Villatoro, Jaime Cordero-Ramos, Rafael Ruiz-Montero, Álvaro Ritoré, Joaquín Dopazo, Jorge Del Diego Salas, Valle García Sánchez, Inmaculada Salcedo-Leal and 3 more

Abstract read
In one paragraph

Article in Journal of epidemiology and global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Álvaro Serrano-Ortiz *Preventive Medicine and Public Health Unit, Reina Sofía University Hospital, Córdoba, Spain.
Juan Luis Romero-Cabrera *Lipids and Atherosclerosis Unit, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.
Jaime Monserrat VillatoroHealth District of Córdoba and Guadalquivir, Córdoba, Spain.
Jaime Cordero-RamosPharmaceutical Management Department, Extremadura Health Service, Mérida, Spain.
Rafael Ruiz-MonteroPreventive Medicine and Public Health Unit, Reina Sofía University Hospital, Córdoba, Spain.
Álvaro RitoréBig Data Department, PMC-FPS, Regional Ministry of Health and Consumer Affairs, Seville, Spain.
Joaquín DopazoInstitute of Biomedicine of Seville (IBiS)/University Hospital Virgen del Rocío/CSIC/University of Sevilla, Seville, Spain.
Jorge Del Diego SalasDirectorate General of Public Health and Pharmaceutical Regulation, Ministry of Health and Consumer Affairs of the Regional Government of Andalusia, Seville, Spain.
Valle García SánchezManagement Directorate of Andalusian Health Service, Ministry of Health and Consumer Affairs of the Regional Government of Andalusia, Seville, Spain.
Inmaculada Salcedo-Leal *Preventive Medicine and Public Health Unit, Reina Sofía University Hospital, Córdoba, Spain.
Miguel Ángel Armengol de la Hoz *Big Data Department, PMC-FPS, Regional Ministry of Health and Consumer Affairs, Seville, Spain. mangel.armengol@juntadeandalucia.es.
Isaac Túnez *Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain.
Miguel Ángel GuzmánAndalusian Public Healthcare System, Andalusia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 vaccination has become a pivotal global strategy in managing the pandemic. Despite COVID-19 no longer being classified as a Public Health Emergency of International Concern, the virus continues affecting people worldwide. This study aimed to evaluate risk factors and vaccine effectiveness on COVID-19-related hospital admissions, intensive care unit (ICU) admission and mortality within the Andalusian population throughout the pandemic.

methodsFrom March 2020 to April 2022, 671,229 individuals, out of 9,283,485 with electronic health records in Andalusia, experienced SARS-CoV-2 infection and were included in the analysis. Data on demographics, medical history, vaccine administration, and hospitalization records were collected. Associations between medical history, COVID-19 vaccines, and COVID-19 outcomes were assessed.

resultsOur study identified 48,196 hospital admissions, 5,057 ICU admissions, and 11,289 deaths linked to COVID-19. Age, male sex, and chronic diseases were identified as risk factors, while the COVID-19 vaccine demonstrated protective effects, although with reduced effectiveness during the omicron variant period. However, the risk for these outcomes increased over time after receiving the last vaccine dose, particularly after six months, especially among those aged 60 or older.

conclusionThe global health challenge of COVID-19 persists, marked by emerging variants with higher virulence and severity, particularly among the unvaccinated and those beyond six months post-vaccination, especially those aged 60 and above. These findings highlight the need for robust surveillance systems targeting new variants and administering booster doses, particularly for individuals aged 60 or older with underlying health conditions, to mitigate the global burden of COVID-19.

Indexed as

COVID-19COVID-19 VaccinesHospitalizationMachine LearningSARS-CoV-2AdolescentAdultAgedAged, 80 and overFemaleHumansIntensive Care UnitsMaleMiddle AgedRisk FactorsSpainCOVID-19 VaccinesCohort studyCOVID-19EpidemiologyHealth policyVaccines

Identifiers

PMID39527397
PMCPMC11652453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.